INTRODUCTION

Top Abstract Introduction Materials & Methods Results Discussion References

Steroid hormones regulate cellular proliferation and differentiation by cell cycle phase-specific actions (40). Estrogen, acting in concert with other hormones and growth factors, appears to be the main drive to proliferation in the female reproductive tract and mammary gland. In contrast with the proliferative effects of estrogen, progesterone acts as the differentiating female sex steroid. In this role it can either stimulate or inhibit proliferation in a cell type- and tissue-specific manner (5). For example, the primary function of progesterone in the uterus is to facilitate implantation, and in this organ progesterone acts synergistically with estrogen to stimulate proliferation of stromal cells but inhibits estrogen-induced mitosis in the epithelium. In the mammary gland progesterone stimulates proliferation and development of alveoli, a requirement for subsequent lactation. In breast cancer cells, a widely used model for studies of the effects of steroids on cell proliferation, treatment with synthetic progestins results in a biphasic change in the rate of cell cycle progression, consisting of an initial transient acceleration through G₁ phase and a subsequent increase in the S phase fraction, followed by cell cycle arrest and growth inhibition accompanied by a decrease in the S phase fraction (23, 25, 38, 55, 61). Thus, two distinct, opposing effects of progestins on cell cycle progression can be observed within the one cell type, emphasizing the complexity of progestin effects on cell proliferation. Data from both breast cancer cells in tissue culture and in vivo studies of the uterus and mammary gland demonstrate that sensitivity to both stimulation and inhibition is present only during G₁ phase (5, 38, 55).

Since endogenous hormones play a key role in the development of hormone-dependent cancers, exposure to exogenous steroid hormones through the use of oral contraceptives and hormone replacement therapies might influence the risk of developing such cancers. Combined oral contraceptives or hormone replacement therapies containing both an estrogen and progestin confer protection from endometrial cancer, while treatment with estrogen alone leads to an increase in risk (46). In contrast, while the effect of hormonal therapies on breast cancer risk has been controversial, there appears to be a slight increase in risk in recent or current users (7, 8), and in postmenopausal women the risk of breast cancer associated with estrogen use does not appear to be reduced by the addition of progestin (6). Thus, progestins appear to be protective against endometrial cancer but not breast cancer. Nevertheless, synthetic progestins have an established role in the therapy of both breast and endometrial cancers (46, 49, 60). The mechanism for the antitumor action of progestins is unknown, but inhibition of breast cancer cell proliferation is a likely contributor. Despite these issues and the role of progesterone in normal mammary development and differentiation, the effects of progesterone and synthetic progestins on cell proliferation have not been widely studied from a mechanistic viewpoint, and mechanisms for progestin inhibition of proliferation remain unidentified at a molecular level. However, the demonstration of steroidal control of cell cycle progression at defined points within G₁ phase (40) suggests that these agents and their antagonists act via their respective receptors to regulate, directly or indirectly, the expression of genes with a central role in the control of cell cycle progression through G₁ phase. Research aimed towards identification of these molecular targets has focused on the roles of c-Myc and cyclins and the associated cyclin-dependent kinases (CDKs) (1, 10, 11, 35, 37, 38, 44, 64).

The sequential activation of CDKs and consequent phosphorylation of specific substrates govern progress through the cell cycle. Key substrates of the CDKs with G₁ phase-specific actions include the retinoblastoma gene product, pRB, and the related protein p107, although it is likely that other substrates remain to be identified: unlike cyclin D1, cyclin E is required for G₁ progression in the absence of functional pRB (reviewed in references 24, 50, and 51). CDK activity is subject to multiple levels of regulation. Since CDKs are inactive in the absence of cyclin binding, cyclin abundance is a major determinant of cyclin-CDK activity (24, 32, 50, 51). Each cyclin is thus typically present for only a restricted portion of the cell cycle. Alteration of cyclin abundance is sufficient to alter the rate of cell cycle progression, since overexpression of either of the principal G₁ cyclins, cyclins D and E, accelerates cells through G₁ and, conversely, inhibition of their function by antibody microinjection prevents entry into S phase (24, 50, 51). CDK activity is also regulated by a network of kinases and phosphatases so that cyclin binding is sufficient only for partial activation (32). The CDK-activating kinase (CAK) phosphorylates a conserved threonine residue in the T-loop of the kinase, stabilizing the cyclin-CDK interaction and altering the conformation of the substrate binding site (33); this phosphorylation is necessary for full activity. Even in the presence of activating phosphorylation at this threonine residue and cyclin binding, CDKs can be inhibited by phosphorylation of threonine and tyrosine residues within the catalytic cleft. The dual-specificity Cdc25 phosphatases activate CDKs by dephosphorylating these inhibitory residues (32). In vertebrate cells three such phosphatases have been identified: Cdc25A, -B, and -C. Cdc25A appears to target CDKs active at the G₁-S transition, since microinjection of anti-Cdc25A antibodies blocked progression from G₁ into S phase (22, 27), while anti-Cdc25C antibodies led to arrest in G₂ phase (31). Overexpression of dominant negative Cdc25B mutants indicates that Cdc25B regulates G₂-M transit (13).

A further level of control results from the actions of two families of specific CDK-inhibitory proteins. One family, for which the prototype is p16^INK4, specifically targets the kinases which associate with the D-type cyclins, Cdk4 and Cdk6. Their inhibitory activity appears to be largely due to competition with the cyclin for CDK binding, although they can also interact with cyclin D-Cdk4 and cyclin D-Cdk6 complexes (21, 45, 51). Members of the other family, of which p21 (WAF1, Cip1, sdi1) and p27 (Kip1) are the best studied, interact with a broader range of CDKs, including Cdk2 as well as Cdk4 and Cdk6. Recent structural studies of p27 bound to cyclin A-Cdk2 have indicated that p27 interacts with both cyclin A and Cdk2, occluding the catalytic cleft and causing multiple structural changes around it (47). Sequence conservation of the residues involved in cyclin and CDK interaction suggests that other members of this inhibitor family probably bind in a similar fashion (47). Both CAK and Cdc25 activation of the kinase are also prevented by inhibitor binding, probably by steric hindrance (2, 48). Despite these multiple modes of inhibition of CDK activity, not all cyclin-CDK complexes containing p21 or p27 are inactive. Histone H1 kinase activity, most likely due to Cdk2, is present in p21 immunoprecipitates (66), perhaps representing an alternate mode of interaction where either the cyclin or CDK, but not both, interacts with p21 (12). Histone H1 activity is not present in p27 immunoprecipitates, although they display pRB kinase activity, apparently due to Cdk4 and Cdk6 (53). Recent data indicate that p21 and p27 as well as a related inhibitor, p57^Kip2, stabilize cyclin D-Cdk4 and cyclin D-Cdk6 complexes in vitro (30). High-stoichiometry p21 or p27 binding appears to be required for inhibition of Cdk4 activity (3, 30). Consequently, these molecules appear to have functions in addition to CDK inhibition, perhaps as adapters which not only promote assembly of the cyclin-CDK complexes but also target these complexes to specific intracellular compartments or substrates.

To identify the sequence of molecular events linking progestin action with inhibition of cell cycle progression, we have examined the effects of progestin treatment of T-47D human breast cancer cells on the abundance and activity of cyclin D1-Cdk4, cyclin D3-Cdk4, and cyclin E-Cdk2, the major G₁ phase CDK complexes in these cells. These experiments demonstrate that progestins not only regulate cyclin abundance but also lead to increased association of the CDK inhibitor p27 with G₁ cyclin-CDK complexes, providing a mechanism for their growth-inhibitory effects in breast cancer cells.

	MATERIALS AND METHODS

Top Abstract Introduction Materials & Methods Results Discussion References

Cell culture. T-47D human breast cancer cells (obtained from the EG & G Mason Research Institute, Worcester, Mass.) were cultured in RPMI 1640 medium supplemented with 5% fetal calf serum, insulin (10 µg/ml), and gentamicin (20 µg/ml). ORG 2058 (16-ethoxy-21-hydroxy-19-norpregn-4-en-3,20-dione; Amersham Australia, Castle Hill, New South Wales, Australia) was dissolved in ethanol at a 1,000- or 2,000-fold final concentration and added to cells in exponential growth. Control cultures received ethanol to the same final concentration. In some experiments untreated control cultures were harvested at the time of ORG 2058 or vehicle addition to the remainder of the replicate cultures.

Generation of recombinant proteins. The pRB fusion protein substrate for the Cdk4 activity assay was a glutathione S-transferase (GST)-pRB construct encoding amino acids 773 to 928 (supplied by Ed Harlow, Massachusetts General Hospital Cancer Center, Charlestown). A restriction fragment of pVL1392 His₆-Cdk2 (44) encompassing the Cdk2 open reading frame was cloned into the expression vector pGEX-2T (Pharmacia, Uppsala, Sweden) to yield a construct encoding the GST-Cdk2 fusion protein used as a substrate for measurement of CAK activity. GST-Cdc25A was generated by using a construct provided by David Beach, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. Escherichia coli transformed with the appropriate expression vectors was induced by the addition of 0.2 to 0.4 mM isopropylthiogalactopyranoside and incubated for 3 h at room temperature. The bacterial pellets were lysed by sonication, and the fusion proteins were purified by affinity chromatography on glutathione-agarose beads and then eluted with 15 mM reduced glutathione.

Western blot analysis and immunoprecipitation. Cells were lysed as follows. Cell monolayers were washed twice with ice-cold phosphate-buffered saline and then scraped into ice-cold lysis buffer (50 mM HEPES [pH 7.5], 150 mM NaCl, 10% [vol/vol] glycerol, 1% Triton X-100, 1.5 mM MgCl₂, 1 mM EGTA, 10 µg of aprotinin per ml, 10 µg of leupeptin per ml, 1 mM phenylmethylsulfonyl fluoride, 200 µM sodium orthovanadate, 10 mM sodium pyrophosphate, 20 mM NaF) or ice-cold kinase lysis buffer (50 mM HEPES [pH 7.5], 1 mM dithiothreitol, 150 mM NaCl, 10% [vol/vol] glycerol, 0.1% Tween 20, 1 mM EDTA, 2.5 mM EGTA, 10 mM -glycerophosphate, 10 µg of aprotinin per ml, 10 µg of leupeptin per ml, 0.1 mM phenylmethylsulfonyl fluoride, 0.1 mM sodium orthovanadate, 1 mM NaF). At selected time points an aliquot of this suspension was diluted in RPMI 1640-5% fetal calf serum and stained for later flow cytometric DNA analysis by addition of ethidium bromide (50 µg/ml) and Triton X-100 (0.2%). Lysates in lysis buffer were incubated for 5 min on ice, and the cellular debris was cleared by centrifugation (15,000 × g, 5 min, 4°C). Lysates in kinase lysis buffer were snap frozen in liquid nitrogen and later thawed on ice, vortexed every 10 min for 60 min, and finally cleared by centrifugation (15,000 × g, 5 min, 4°C). The cleared lysates were aliquoted and stored at 80°C. Similar results were obtained from Western blotting or immunoprecipitation by either lysis technique.

Kinase assays. The histone H1 kinase activity of cyclin E immunoprecipitates (100 µg of cell lysate) was measured as previously described (37, 44) with 10 µg of histone H1 as the substrate. There was little or no detectable phosphorylation in samples immunoprecipitated by using beads without antibody or following blocking of specific antibody binding with the appropriate antigenic peptide. For Cdk4 assays, cells were harvested and lysed by using kinase lysis buffer as described above. The kinase activity of Cdk4 immunoprecipitates of >400 µg of these lysates was measured by using 10 µg of GST-pRB^773-928 fusion protein substrate as previously described (44). The degree of background phosphorylation in each pRB phosphorylation assay was estimated from parallel control samples immunoprecipitated either by using beads without antibody or following blocking of specific antibody binding with the appropriate antigenic peptide. The two controls yielded similar amounts of background phosphorylation.

RNA isolation and Northern analysis. Total RNA was extracted (by a guanidinium isothiocyanate-cesium chloride procedure) and blotted as previously described, using 20 µg of total RNA/lane (4). Filters were hybridized (overnight, 50°C) with cDNA probes radioactively labelled with [-³²P]dCTP to a specific activity of approximately 10⁹ cpm/µg of DNA by using the Prime-A-Gene labelling kit (Promega Australia, Annandale, New South Wales, Australia). Restriction enzyme digestion was used to provide the listed fragments from plasmids supplied by the following investigators: cyclin D1, a 1.3-kb EcoRI fragment encompassing the entire open reading frame (David Beach, Cold Spring Harbor Laboratory); cyclin E, a 2.5-kb EcoRI fragment encompassing the entire open reading frame (Steven Reed, Scripps Research Institute, La Jolla, Calif.); Cdc25A, a 2.3-kb EcoRI fragment encompassing the entire open reading frame (David Beach); c-myc, a 0.45-kb PstI fragment corresponding to the second exon (Geoff Symonds, RW Johnson Pharmaceutical Research Institute, Sydney, New South Wales, Australia); and 36B4, a 0.22-kb PstI fragment (Pierre Chambon, Institut de Genetique et de Biologie Moleculaire et Cellulaire, Strasbourg, France).

Cdc25A activation assay. Cyclin E or Cdk4 immunoprecipitates were washed twice in lysis buffer or kinase lysis buffer, respectively, without phosphatase inhibitors and twice in phosphatase buffer containing 50 mM HEPES (pH 8.2), 15 mM MgCl₂, 1 mM dithiothreitol, and 1 mM ATP. The immunoprecipitates were incubated with GST-Cdc25A in phosphatase buffer for at least 1 h at 30°C and then washed twice in lysis buffer and twice in 10 mM HEPES (pH 7.5)-1 mM dithiothreitol. Kinase activity was assayed as described above.

Gel filtration. Cell lysates prepared in kinase lysis buffer were passed through a 0.22-µm-pore-size MILLEX-GV4 filter (Millipore, Lane Cove, New South Wales, Australia) and fractionated on a Hiload 16/60 Superdex 200 column-fast protein liquid chromatography system (Pharmacia Biotech, Uppsala, Sweden) with 20 mM HEPES (pH 7.5)-250 mM NaCl-1 mM EDTA-0.1% (vol/vol) -mercaptoethanol-0.01% Tween 20 at a flow rate of 1.2 ml/min. The void volume of the column was 45 ml. Either 2- or 3-ml fractions were collected between elution volumes of 55 and 95 ml. Column calibration was performed under the same conditions with ferritin (440 kDa), aldolase (158 kDa), and ovalbumin (43 kDa). Protein was concentrated prior to Western blotting: 500 µl of each fraction was placed at 70°C for 3 h with 2.5 ml of acetone and 10 µg of carrier bovine serum albumin protein, and pellets were collected by centrifugation (15,000 × g, 10 min, 4°C) and then resuspended by boiling for 4 min in 30 µl of SDS sample buffer.

	RESULTS

Top Abstract Introduction Materials & Methods Results Discussion References

Previous experiments in this laboratory characterized the effects of synthetic progestins on the cell proliferation kinetics of human breast cancer cell lines, particularly T-47D, and defined a biphasic response consisting of initial acceleration of cell cycle progression and subsequent inhibition of proliferation (38, 55). The relative magnitudes of the two components of the response are dependent in part on the growth rate and hence on the culture conditions. To emphasize the growth-inhibitory response, for the present series of experiments cells were cultured under conditions leading to optimal growth rates, i.e., in medium supplemented with insulin and fetal calf serum. Consistent with previous data (38, 55), treatment with a maximally effective concentration of the progestin ORG 2058 (10 nM) led to an initial small increase in the S phase fraction, followed by arrest in G₁ phase and consequent accumulation of G₁ phase cells at the expense of the other phases of the cell cycle (Fig. 1). Inhibition of entry into S phase was first apparent after 18 h of treatment, as indicated by a relative lack of cells in early S phase (Fig. 1A), although the S phase fraction had not yet decreased significantly below that of control cells (Fig. 1B). The decrease in the S phase fraction was maximal at 24 h (Fig. 1B), and the G₂-plus-M fraction subsequently decreased (Fig. 1A) such that by 30 h up to 86% of the cells were in G₁ phase.

View larger version (17K): [in this window] [in a new window]   FIG. 1.   Progestin inhibition of cell cycle progression. Exponentially proliferating T-47D breast cancer cells were treated with the synthetic progestin ORG 2058 (10 nM) or vehicle (Control). At intervals thereafter, cells were lysed and an aliquot was stained for flow cytometric measurement of DNA content. (A) Representative DNA histograms. (B) Percentages of control cells () or ORG 2058-treated cells () in S phase. Data from a total of six experiments have been pooled and are shown as means ± SEMs, where the SEM exceeds the size of the symbol used.

Inhibition of G₁ CDK activity and reduced phosphorylation of pRB and p107 following progestin treatment. Initial experiments examined the phosphorylation of pRB and p107, in vivo substrates of G₁ CDKs. In control exponentially proliferating cells both phosphorylated and underphosphorylated pRB were apparent, although the underphosphorylated form comprised only ~20% of the total (Fig. 2A and B). Little change in the proportions of phosphorylated and underphosphorylated pRB was apparent at 6 or 12 h after progestin treatment (Fig. 2A and B), although there was a slight, <50%, increase in the total pRB abundance and a consequent increase in the absolute amount of underphosphorylated pRB at 12 h (Fig. 2C). By 18 h the proportion of pRB in the underphosphorylated form had begun to increase, and after 24 h or more, 70 to 80% of pRB was in this form (Fig. 2A and B). Although the total pRB abundance decreased by ~50% at 24 to 30 h, the large increase in the proportion of underphosphorylated pRB resulted in an ~2-fold increase in the abundance of the underphosphorylated form from 18 to 30 h (Fig. 2C). Phosphorylated pRB, detected by antibodies recognizing either the whole molecule or a site specifically phosphorylated by cyclin D1-Cdk4 (RB-P-Ser780 [29]), began to decrease in abundance by 18 h and was markedly reduced by 24 h (Fig. 2). The effects of progestin treatment on p107 phosphorylation and abundance paralleled those on pRB: at 18 h more underphosphorylated p107 was apparent, and after 24 h or more, p107 was largely unphosphorylated and reduced in total abundance (Fig. 2A). Comparison of the data in Fig. 1B and 2C indicated that the accumulation of underphosphorylated pRB reached its maximum by 18 h, a time when little change in the S phase fraction was detected, and thus accumulation of the inhibitory form of pRB preceded the inhibition of entry into S phase by up to 6 h.

View larger version (25K): [in this window] [in a new window]   FIG. 2.   Progestin effects on pRB and p107. Exponentially proliferating T-47D breast cancer cells were treated with the synthetic progestin ORG 2058 (10 nM) or vehicle. At intervals thereafter whole-cell lysates were immunoblotted with antibodies raised against pRB, p107, or a pRB-derived phosphopeptide that contains a cyclin D1-Cdk4-specific target (RB-P-Ser780). (A) Representative blots from one of five experiments (pRB) or two experiments (p107 and RB-P-Ser780). (B) The slower-mobility (hyperphosphorylated) ( and ) and faster-mobility (hypophosphorylated) ( and ) forms of pRB in the blot shown in panel A were quantitated by densitometry and are presented as the proportion of total pRB for both control cells (open symbols) and ORG 2058-treated cells (closed symbols). (C) Raw densitometric measurements of pRB abundance after ORG 2058 treatment for the representative blot shown in panel A. For clarity, data from control lanes have been pooled and are presented (means ± SEMs) as the 0-h points. , total; , hyperphosphorylated; , hypophosphorylated. arb., arbitrary.

View larger version (27K): [in this window] [in a new window]   FIG. 3.   Progestin inhibition of CDK activity. Exponentially proliferating T-47D breast cancer cells were treated with the synthetic progestin ORG 2058 (10 nM) or vehicle. At intervals thereafter whole cell-lysates were prepared and immunoprecipitated with antibodies to Cdk4 or cyclin E. Either GST-pRB773-928 (Cdk4 activity) or histone H1 (cyclin E-Cdk2 activity) was used as a substrate. (A) The upper panel shows phosphorylated GST-pRB773-928 from a representative experiment, visualized by SDS-PAGE and autoradiography. The first lane (+ pep) contains a sample from untreated cells harvested at the time of ORG 2058 or vehicle addition, in which the immunoprecipitation was performed in the presence of competing antigenic peptide. The lower panel shows phosphorylated histone H1 from a representative experiment visualized by SDS-PAGE and autoradiography. (B) Phosphorylated substrates were detected with PhosphorImager. Points represent the means ± SEMs from two to four observations, relative to the average control value for each experiment. For Cdk4 activity the background in each assay was estimated from samples immunoprecipitated in the presence of competing peptide or in the absence of antibody and has been subtracted from the individual data points. , Cdk4 activity; , cyclin E-Cdk2 activity.

Decreased expression of cyclins D1, D3, and E and increased expression of the CDK inhibitors p21 and p27 following progestin treatment. To investigate possible causes of the decreased kinase activity, the expression of components of the G₁ cyclin complexes was examined. Cyclin D1 protein initially slightly increased in abundance (Fig. 4). However, this was transient, and at 18 to 24 h cyclin D1 levels in progestin-treated cells were ~50% of those in control cells (Fig. 4). Northern analysis showed that, similarly, cyclin D1 mRNA was initially induced but subsequently declined to ~60% of control at 18 h, remaining below control levels at 24 h (Fig. 4C). A slight decrease in cyclin E protein expression was apparent as early as 12 h, and the decline continued until cyclin E reached a minimum of 25% of the control value at 24 h (Fig. 4). Consistent with the partial recovery of cyclin E-associated kinase activity observed at 30 h (Fig. 3), cyclin E expression partially recovered between 24 and 30 h to reach 50% of the control value (Fig. 4). The cyclin E mRNA abundance was reduced following 18 to 24 h of progestin treatment, to ~50% of the control value or less (Fig. 4C). The changes in cyclin D1 and E mRNAs were similar in timing and magnitude to the changes in protein abundance, suggesting that progestin treatment regulated cyclin D1 and E expression in large part via transcriptional mechanisms. No significant changes in cyclin D3, Cdk2, or Cdk4 protein expression were apparent until 24 h after progestin treatment, when decreases of 40 to 50% were observed; the decreases were maintained at 30 h (Fig. 4). The abundance of p21 protein did not change until 18 h, when it increased ~2-fold; the increase was maintained at 24 h but was of smaller magnitude thereafter (Fig. 5). Upon more extended progestin treatment, p21 levels fell below control values (see Fig. 12). The abundance of p27 began to increase slightly at 18 to 24 h and had increased approximately twofold at 30 h (Fig. 5). Thus, of the proteins examined, only cyclin D1, cyclin E, and p21 displayed alterations in abundance of 2-fold at 18 h, when marked decreases in Cdk4 activity and cyclin E-associated kinase activity were observed.

View larger version (37K): [in this window] [in a new window]   FIG. 4.   Cyclin and CDK expression following progestin treatment. Exponentially proliferating T-47D breast cancer cells were treated with the synthetic progestin ORG 2058 (10 nM) or vehicle, and at intervals thereafter whole-cell lysates or total cellular RNA were prepared. (A) Representative Western blots for cyclin D1, cyclin D3, cyclin E, Cdk2, and Cdk4. UT, untreated control harvested at the time of treatment. (B) Data representing the means ± SEMs from three to five observations (cyclin D1), three or four observations (cyclin D3), or two to four observations (cyclin E) are expressed relative to the average control value in each experiment. (C) Representative Northern blots for cyclin D1, cyclin E, and, as a control for RNA loading on the cyclin E blot, 36B4. The loading control for the cyclin D1 blot is shown in Fig. 6.

View larger version (26K): [in this window] [in a new window]   FIG. 5.   CDK inhibitor expression following progestin treatment. Exponentially proliferating T-47D breast cancer cells were treated with the synthetic progestin ORG 2058 (10 nM) or vehicle, and at intervals thereafter whole-cell lysates were prepared. (A) Representative Western blots for p21 and p27. (B) Data representing the means ± SEMs from three to six (p21) or four or five (p27) observations are expressed relative to the average control value in each experiment.

Changes in Cdc25 or CAK activity do not account for progestin-induced decreases in CDK activity. Further experiments examined the possibility that altered CDK phosphorylation might contribute to the decrease in activity following progestin treatment. First, regulation of phosphorylation at inhibitory residues within the catalytic cleft was addressed, since such inhibition is dominant over activation resulting from either cyclin binding or CAK activation (see the introduction). Of the family of phosphatases responsible for relieving this inhibition, Cdc25A appears to have specificity for G₁ CDKs in vivo, and therefore its expression was examined. Following ORG 2058 treatment a small increase of <50% was apparent at 6 h, but thereafter Cdc25A mRNA decreased in abundance to reach a minimum of ~30% of the control value at 18 to 24 h (Fig. 6A). In view of evidence for c-myc regulation of Cdc25A (14), c-myc expression was also examined. Consistent with previous data (38, 65), progestin treatment increased c-myc expression after 1 h, but thereafter c-myc expression decreased to <50% of the control value (Fig. 6A). The decrease in c-myc expression was apparent within 6 h, thus preceding the decline in Cdc25A expression by >12 h. Measurement of Cdc25A protein levels revealed only an ~50% decrease in abundance at 18 to 24 h (Fig. 6B).

View larger version (62K): [in this window] [in a new window]   FIG. 6.   Cdc25A and c-myc expression following progestin treatment. Exponentially proliferating T-47D breast cancer cells were treated with the synthetic progestin ORG 2058 (10 nM) or vehicle (Control), and at intervals thereafter total cellular RNA or whole-cell lysates were prepared. (A) Representative Northern blot sequentially probed with Cdc25A, c-myc, and 36B4 (as a control for RNA loading). (B) Representative Western blot for Cdc25A. UT, untreated cells harvested at the time of treatment.

View larger version (47K): [in this window] [in a new window]   FIG. 7.   Regulation of Cdc25 or CAK activity does not account for decreased CDK activity following progestin treatment. (A) Replicate cyclin E immunoprecipitates from 250 µg of lysate prepared from exponentially proliferating T-47D cells were incubated with increasing amounts of GST-Cdc25A (170, 340, 680, and 1,360 µg) or GST (360 and 1,440 µg) or without further addition () at 30°C for 1 h and washed, and then kinase activity was measured with a histone H1 substrate. One sample (Van) was incubated with 680 µg of GST-Cdc25A in the presence of the phosphatase inhibitors vanadate (10 mM) and NaF (50 mM). (B) T-47D breast cancer cells were treated with the synthetic progestin ORG 2058 (10 nM) or vehicle for 24 h. Cyclin E immunoprecipitates were incubated with or without Cdc25A as indicated, and cyclin E-Cdk2 activity was measured with a histone H1 substrate. Parallel immunoprecipitates were Western blotted with Cdk2 antibodies. (C) Cdk4 immunoprecipitates from control or ORG 2058-treated (10 nM, 30 h) cells were incubated with GST-Cdc25A, and Cdk4 activity was measured with GST-pRB773-928. (D) The kinase activity of Cdk7 immunoprecipitates from control or ORG 2058-treated T-47D cells was measured with a GST-Cdk2 substrate. The first lane (+ pep) contains a sample from untreated cells in which the immunoprecipitation was performed in the presence of competing antigenic peptide.

Progestin treatment alters the molecular mass of cyclin E complexes but not cyclin D complexes. The data presented in Fig. 7 argued that changes in CDK phosphorylation were unlikely to contribute to the decreases in Cdk4 and cyclin E-associated kinase activities. This suggested that alterations in either the abundance or composition of the CDK complexes were probable mechanisms for the decreased kinase activity. Since recent data have indicated that CDK complexes with different compositions and activities can be resolved by gel filtration chromatography (for example, see references 44 and 54), lysates from control and progestin-treated cells were fractionated to determine whether progestin treatment affected the formation or composition of these complexes. Aliquots of protein eluted from a Superdex 200 column were acetone precipitated and Western blotted. In control lysates cyclin D1 typically eluted in a single major broad peak with an apparent molecular mass of ~160 kDa (Fig. 8A), consistent with previous data from Superose 12 fractionation of Swiss 3T3 cells (42); in some experiments (e.g., that shown in Fig. 8), a proportion also eluted at a lower apparent molecular mass (Fig. 8A). The majority of cyclin D3 coeluted with cyclin D1 at ~160 kDa, but a form with a lower apparent molecular mass was consistently observed. Since the lower-molecular-mass forms of cyclin D1 and D3 coeluted with cyclin D1 produced by in vitro transcription and translation in reticulocyte lysate (data not shown), it is likely that these represent free cyclin D. Cyclin E eluted over a broad range of apparent molecular mass, indicating the presence of two overlapping peaks with apparent molecular masses of ~120 and ~200 kDa (Fig. 8B and 9; see also Fig. 12).

View larger version (48K): [in this window] [in a new window]   FIG. 8.   Elution profiles of cyclins, CDKs, and CDK inhibitors in control and progestin-treated lysates. Exponentially proliferating T-47D breast cancer cells were treated with the synthetic progestin ORG 2058 (10 nM) or vehicle (Control) for 24 h. Whole-cell lysates were fractionated on a Superdex 200 gel filtration column (void volume, 45 ml). The elution volumes of markers with known molecular masses (ferritin, 440 kDa; aldolase, 158 kDa) are indicated; ovalbumin (43 kDa) eluted at 85 ml, corresponding to fraction 15. Fractions (2 ml) corresponding to elution volumes of 57 to 82 ml were acetone precipitated and then Western blotted for the proteins indicated.

View larger version (44K): [in this window] [in a new window]   FIG. 9.   Time course of changes in elution profiles of cyclin E, p21, and p27 following progestin treatment. Exponentially proliferating T-47D breast cancer cells treated with the synthetic progestin ORG 2058 (10 nM) or vehicle (Control) in the same experiment as presented in Fig. 8 were harvested after 12 or 18 h. Whole-cell lysates were fractionated on a Superdex 200 gel filtration column (void volume, 45 ml). The elution volumes of markers with known molecular masses (ferritin, 440 kDa; aldolase, 158 kDa) are indicated; ovalbumin (43 kDa) eluted at 85 ml, corresponding to fraction 15. (A) Fractions (2 ml) corresponding to elution volumes of 57 to 80 ml were acetone precipitated and then Western blotted for the proteins indicated. (B) Western blots of 2-ml fractions were quantitated by densitometry and are presented as percentages of the total signal observed for each protein. Data from three control samples (12, 18, and 24 h of vehicle treatment) have been pooled and are presented as means ± SEMs, where the SEM exceeds the size of the symbol. , control; , ORG 2058.

Increased association of p27 but not p21 with cyclin D-Cdk4 complexes following progestin treatment. Since the data presented in Fig. 8 indicated that the majority of cyclin-CDK complexes might also contain CDK inhibitors, in further experiments immunoprecipitates of fractionated lysates were used in in vitro kinase assays to determine which fractions contained active CDK. In view of the limited sensitivity of Cdk4 assays, Cdk4 activity was measured in 3-ml fractions rather than in 2-ml fractions. Cdk4 activity from control lysates displayed an elution profile similar to that of the high-molecular-mass form of Cdk4, reaching a maximum at 150 to 200 kDa (compare Fig. 8A and 10). However, consistent with data obtained with whole-cell lysates (Fig. 3), progestin treatment resulted in a marked decrease in Cdk4 activity (Fig. 10A). Western blotting of Cdk4 immunoprecipitates from fractionated control lysates indicated that the active fractions contained significant amounts of coimmunoprecipitating cyclin D1, cyclin D3, Cdk4, p21, and p27 (Fig. 10B). The same fractions from progestin-treated lysates contained less Cdk4 and significantly less cyclin D1 and cyclin D3, consistent with the decrease in total abundance of these proteins (Fig. 10B). However, no increase in p21 was observed, and in some experiments the abundance of p21 appeared to decrease relative to the abundance of other components of the complex following progestin treatment (Fig. 10B). In contrast, the decrease in the amount of cyclin D1 and cyclin D3 in the Cdk4 immunoprecipitates was more marked than the decrease in the amount of associated p27 (Fig. 10B). In fraction 3, the abundance of cyclin D3 decreased by ~60% while the abundance of p27 changed little, such that the p27/cyclin D3 ratio increased 2.3-fold. Similarly, in fraction 5, the abundance of cyclin D1 decreased by >50% and there was a smaller decrease in the amount of p27, such that the p27/cyclin D1 ratio increased ~2-fold. These data suggest that the decreased abundance of cyclins D1 and D3 is a major factor in the decrease in Cdk4 activity but that increased p27 association also likely contributes to the loss of activity.

View larger version (54K): [in this window] [in a new window]   FIG. 10.   Cdk4 activity and complex composition of fractionated T-47D lysates. Exponentially proliferating T-47D breast cancer cells were treated with the synthetic progestin ORG 2058 (10 nM) or vehicle (Control) for 24 h. Whole-cell lysates were fractionated on a Superdex 200 gel filtration column, and 3-ml fractions corresponding to elution volumes of 58 to 81 ml were then immunoprecipitated with a Cdk4 antibody. (A) Kinase activities of the immunoprecipitates were measured with a GST-pRB773-928 substrate. (B) Immunoprecipitates of the fractions indicated were Western blotted with the antibodies indicated.

The low-activity form of cyclin E is associated with CDK inhibitors. Measurement of kinase activity in cyclin E immunoprecipitates from gel filtration fractions revealed a peak of activity associated with the 120-kDa form of cyclin E in control cells (fractions 8 to 10) but much less activity in fractions 4 to 7, associated with the ~200-kDa form (Fig. 11A), although similar amounts of cyclin E were present in the two forms (Fig. 8B and 9). Some activity, comprising up to ~20% of the total, was present in the fractions with very high apparent molecular masses (>400 kDa). Following progestin treatment, near-background levels of kinase activity were observed in fractions 8 to 11, consistent with the lack of cyclin E in these fractions, and little activity could be detected associated with the remaining major ~200-kDa peak of cyclin E protein (Fig. 11A). The peak of activity in fraction 4 of progestin-treated lysate in Fig. 11A was not consistently observed. Thus, while kinase activity was reduced across the elution profile, this was most marked in the fractions corresponding to the 120-kDa form of cyclin E. 

View larger version (48K): [in this window] [in a new window]   FIG. 11.   Cyclin E-Cdk2 activity and complex composition of fractionated T-47D lysates. Exponentially proliferating T-47D breast cancer cells were treated with the synthetic progestin ORG 2058 (10 nM) or vehicle (Control) for 24h. Whole-cell lysates were fractionated on a Superdex 200 gel filtration column, and fractions were then immunoprecipitated with a cyclin E antibody. (A) Kinase activities of immunoprecipitates corresponding to elution volumes of 59 to 61 (fractions 2 and 3), and 63 to 78 ml in 2-ml increments (fractions 4 to 11) were measured with a histone H1 substrate. (B) Immunoprecipitates from fractions encompassing the peak of cyclin E protein were resuspended in 25 µl of SDS sample buffer, and various volumes were Western blotted in parallel with the antibodies indicated. (C) Cyclin E immunoprecipitates corresponding to elution volumes of 65 to 68 ml (fractions 5 and 6) and 72 to 74 ml (fractions 8 and 9) were Western blotted with a Cdk2 antibody.

Cyclin D1 induction in progestin-inhibited cells leads to a reinitiation of cell cycle progression and altered molecular mass of cyclin E complexes. To determine to what degree reduced cyclin expression contributed to the reduction in CDK activity and inhibition of cell cycle progression following progestin treatment, a clonal derivative of T-47D cells expressing cyclin D1 under the control of the heavy-metal-responsive metallothionein promoter, T-47D MTcycD1-3, was treated with progestin for 24 to 48 h to inhibit cell cycle progression and then with zinc to induce cyclin D1 expression. Induction of cyclin D1 was sufficient to stimulate a cohort of progestin-inhibited cells to resume cell cycle progression, such that the S phase fraction, 10% after progestin pretreatment, increased to a maximum of >40% after zinc treatment (Fig. 12A). Zinc treatment of cells pretreated with vehicle rather than progestin increased the proportion of cells in S phase to a similar maximum level, although the relative increase was smaller due to the higher S phase fraction in the absence of progestin pretreatment (Fig. 12A). Western blots of cells harvested after zinc treatment of either vehicle- or progestin-pretreated cells demonstrated marked induction of cyclin D1 in progestin-pretreated cells and more modest induction of cyclin D1 in vehicle-pretreated cells (Fig. 12B). In progestin-pretreated cells cyclin D1 induction restored cyclin E expression to a level similar to that observed in cells not treated with progestin, consistent with the observation that cyclin D1 induction of cell cycle progression in these cells leads to induction of cyclin E (39), but had little effect on the abundances of p21 and p27. Induction of cyclin D1 in progestin-pretreated cells also increased Cdk4 activity and cyclin E-Cdk2 activity to levels similar to that following cyclin D1 induction in vehicle-pretreated cells (Fig. 12B).

View larger version (53K): [in this window] [in a new window]   FIG. 12.   Resumption of cell cycle progression after cyclin D1 induction in progestin-pretreated cells. Exponentially proliferating T-47D MTcycD1-3 breast cancer cells, expressing cyclin D1 under the control of a zinc-inducible promoter, were pretreated with the synthetic progestin ORG 2058 (10 nM) or vehicle (ethanol [EtOH]) and then treated with either zinc (ZnSO4) or vehicle (water). (A) Percentages of cells in S phase after 24 h of ORG 2058 or EtOH pretreatment followed by 15 h of zinc (50 µM) or water treatment. (B) Lysates harvested from cells pretreated for 30 h with either ORG 2058 or EtOH followed by 15 h of zinc (75 µM) or water treatment were Western blotted for the indicated proteins or immunoprecipitated with either Cdk4 or cyclin E antibodies for measurement of kinase activity as described in the legend to Fig. 3. (C) Whole-cell lysates from the experiment presented in panel B were fractionated on a Superdex 200 gel filtration column (void volume, 45 ml). Fractions (2 ml) corresponding to elution volumes of 57 to 82 ml were acetone precipitated and then Western blotted for the proteins indicated. The elution volumes of markers with known molecular masses (ferritin, 440 kDa; aldolase, 158 kDa) are indicated; ovalbumin (43 kDa) eluted at 85 ml, corresponding to fraction 15. (D) The Western blots presented in panel C were quantitated by densitometry and are presented as percentages of the total signal observed for each protein.

	DISCUSSION

Top Abstract Introduction Materials & Methods Results Discussion References

This study has focused on regulation of CDK activity accompanying growth inhibition by the progestin ORG 2058 as a step towards dissecting the mechanisms that mediate progestin effects on normal physiology and on breast cancer. Marked decreases in both Cdk4 activity and cyclin E-Cdk2 activity, with consequent decreases in the phosphorylation of pRB and p107, preceded inhibition of entry into S phase. Several different molecular events potentially contributing to the decrease in CDK activity were observed: initial alterations in the abundances of cyclin D1 and cyclin E, later changes in the abundances of cyclin D3 and p27, and increased relative p27 association with cyclin D-Cdk4 and cyclin E-Cdk2 complexes. These events were all preceded by an early decline in c-myc expression, first apparent within 3 to 6 h of progestin treatment.

Since both Cdk4 activity and cyclin E-Cdk2 activity are required for progress from G₁ into S phase (24, 50, 51), the observed decrease in these activities (Fig. 3) could account for progestin-mediated inhibition of proliferation. Substrates for these CDKs, including pRB and p107, can thus be seen as the eventual targets for this aspect of progestin action. Both pRB and p107 decreased in total abundance as well as phosphorylation, such that very little of the phosphorylated form of either protein was present following 24 h or more of progestin treatment. However, despite the decrease in total abundance, the underphosphorylated form was increased in abundance, reaching a maximum by 18 h, which was maintained until at least 30 h. Thus, the accumulation of the growth-inhibitory forms of these proteins preceded the inhibition of entry into S phase, which was first apparent at 18 h. The partial recovery of cyclin E-associated kinase activity between 24 and 30 h was not accompanied by a detectable increase in pRB phosphorylation. Since at that time little Cdk4 activity was present, this observation is consistent with the view that cyclin E-Cdk2 phosphorylation of pRB is dependent on prior pRB phosphorylation by cyclin D-associated kinases (19). However, it is also possible that the recovery of cyclin E-Cdk2 activity is sufficient to overcome the lack of Cdk4 activity in a fraction of the cell population, thus contributing to the slow resumption of proliferation following extended progestin treatment (55). Induction of differentiation is a major physiological role of progestins (5), but the decrease in pRB abundance following progestin treatment contrasts with the frequent observation of increased pRB expression accompanying differentiation in diverse cell types (9, 52, 57). However, since the mammary gland differs from most other tissues in that differentiation is followed by involution, some differences in control of differentiation may be expected. In this context it is interesting that pRB deficiency is associated with increased apoptosis (63).

Examination of potential mechanisms for the decrease in CDK activity accompanying progestin inhibition of proliferation revealed decreased expression of mRNA encoding the CDK-activating phosphatase Cdc25A. Reduced Cdc25A expression and increased tyrosine phosphorylation of Cdk2 and Cdk4 have been implicated in growth arrest by different agents, including UV irradiation, alpha interferon, and transforming growth factor  (TGF-) (26, 58, 59). In addition, since cyclin E-Cdk2 activates Cdc25A by phosphorylation (22), decreased Cdc25A expression in combination with decreased cyclin E-Cdk2 activity might result in marked decreases in Cdc25A activity. Thus, lack of Cdc25A activity provided an attractive mechanism contributing to reduced CDK activity following progestin treatment. However, the decrease in Cdc25A protein levels was less marked than the decrease in the corresponding mRNA, consistent with the suggestion that the protein may have a long half-life (26). Furthermore, treatment with recombinant Cdc25A failed to restore the activity of cyclin E-associated kinases to a level consistent with the level of Cdk2 present in the complexes, and no Cdc25A activation of Cdk4 from either control or progestin-treated lysates was observed. Although the possibility that the amount of Cdc25A used was insufficient to activate Cdk4 cannot be excluded, this result is consistent with the lack of tyrosine phosphorylation on Cdk4 and Cdk6 (but not Cdk2) in exponentially proliferating MCF10A mammary epithelial cells (26). These data indicate that regulation of Cdc25A does not make a major contribution to progestin inhibition of proliferation.

The initial progestin-mediated decreases in Cdk4 and cyclin E-Cdk2 activity were accompanied by alterations in the abundances of several of the components of these complexes, i.e., cyclin D1, cyclin E, and p21. Separation of whole-cell lysates by gel filtration chromatography indicated that cyclin E and Cdk2 displayed a distinct alteration in elution profile following progestin treatment. In control cells the major peak of cyclin E-associated kinase activity eluted at ~120 kDa, although some activity, ~20% of the total, was present in complexes of very high molecular mass. A significant fraction of the cyclin E in control cells eluted at ~200 kDa and displayed relatively little associated kinase activity, likely due to p21 and p27 association. This observation is consistent with other data indicating that cyclin E is present in a largely inactive ~250-kDa form and a more active ~120-kDa form (54) and that a minority of cyclin E accounts for the majority of the associated kinase activity (41, 44). Following progestin treatment, almost all of the cyclin E was in a low-activity, p21- and p27-bound form eluting at ~200 kDa. This peak of cyclin E also contained less CAK-activated Cdk2 than the corresponding fractions from a control lysate, consistent with data demonstrating that these CDK inhibitors interfere with activation by CAK (2). Thus, the reduced number of cyclin E-Cdk2 complexes present following progestin treatment preferentially assemble into the less active CDK-inhibitor bound form at the expense of the more active 120-kDa form. This redistribution preceded the inhibition of entry into S phase and coincided with the inhibition of cyclin E-Cdk2 activity, implicating it as a cause of the inhibition of kinase activity. Further evidence for a causative link between the redistribution of cyclin E-Cdk2 complexes and their activity is provided by the observation that following cyclin D1 induction in progestin-pretreated cells, the more active 120-kDa form of cyclin E-Cdk2 reappeared and kinase activity was restored at a time when the majority of the stimulated population had yet to reenter S phase. These data also suggest that alterations in cyclin abundance, especially cyclin D1 abundance, are sufficient to lead to changes in the compositions as well as the relative abundances of various cyclin-CDK complexes.

Cyclin D1 and cyclin D3 differed from cyclin E in that the cyclin-CDK complexes and the associated kinase activity displayed the same elution profile, peaking at ~160 kDa, although this peak clearly contained p21- and p27-bound CDK (Fig. 10). This is consistent with data indicating that p21 and p27 association with Cdk4 does not necessarily inhibit kinase activity (3, 30, 53), and indeed, some pRB kinase activity was present in p27 immunoprecipitates from exponentially proliferating T-47D cells, equivalent to approximately a third of the Cdk4 activity (data not shown). Following progestin treatment, although major shifts in the elution profile of cyclin D1, cyclin D3, or Cdk4 were not observed, Cdk4 immunoprecipitates of fractionated lysates contained less cyclin D1 and cyclin D3 and had an increased p27/cyclin D ratio (Fig. 10). Overall, these data suggest that a major factor in the decrease in Cdk4 activity following progestin treatment is a decrease in the abundance of the cyclin D1-Cdk4 and cyclin D3-Cdk4 complexes and that increased p27 association with these complexes may contribute to their decreased kinase activity. The ability of ectopic cyclin D1 induction to reinitate cell cycle progression following progestin pretreatment is consistent with this conclusion.

The data presented above indicate a redistribution of p27 between different cyclin-CDK complexes at times when there was little alteration in p27 abundance. Furthermore, although the p21 abundance increased ~2-fold following progestin treatment, there appeared to be no corresponding recruitment of p21 into either cyclin E-Cdk2 complexes or Cdk4 complexes. One explanation for the latter observation might be that following progestin treatment p21 was in excess over the number of available binding sites, but gel filtration indicated that neither p21 nor p27 was present in monomeric form except after extended progestin treatment. Furthermore, immunoprecipitation studies indicated that the majority of p21 and p27 is associated with cyclin D1 and Cdk4, in either the presence or absence of progestin treatment (reference 37 and data not shown). In contrast, while a significant proportion of cyclin E is associated with p21 and p27, this accounts for a small fraction (<10%) of the total pool of these CDK inhibitors.

One important factor in the formation of complexes between these proteins is the relative affinities of the CDK inhibitors for different cyclin-CDK complexes, and this, combined with the reduction in the abundance of several cyclin-CDK complexes, suggests a possible explanation for the redistribution of these CDK inhibitors. Experiments using purified components have indicated that the affinity of p27 for cyclin E-Cdk2 is ~10-fold higher than its affinity for cyclin D2-Cdk4, while in contrast, p21 has a higher affinity for cyclin D2-Cdk4 than for cyclin E-Cdk2 (18). If cyclin D1-Cdk4 and cyclin D3-Cdk4 have affinities for p27 similar to that of cyclin D2-Cdk4, cyclin D-Cdk4 complexes are likely to act as high-capacity, low-affinity binding sites for p27, consistent with the idea that they represent a sink for p27 (24, 50, 51). Thus, the data are consistent with the interpretation that a relatively small decrease in the abundance of cyclin D-Cdk4 complexes makes sufficient p27 available for cyclin E-Cdk2 binding to account for its redistribution following progestin treatment, and conversely, induction of cyclin D1 sequesters p27 in cyclin D1-Cdk4 complexes, favoring the formation of the more active, p27-depleted form of cyclin E-Cdk2. Thus, increased p27 association with cyclin E-Cdk2 following progestin treatment may be a consequence of the decreased abundances of cyclins D1 and D3. In contrast with p27, the lower relative affinity of p21 for cyclin E-Cdk2 suggests that upon reduction in cyclin D-Cdk4 complex numbers, it would compete poorly with p27 for the available cyclin E-Cdk2 and in consequence associate with other cyclin-CDK complexes, perhaps cyclin A-Cdk2, for which it displays an affinity similar to its affinity for cyclin D2-Cdk4 (18). This suggestion is consistent with observations that following progestin treatment, an increased proportion of p21 was present in the fractions containing cyclin A-Cdk2 (~300 kDa) and that Cdk2 immunoprecipitates contained increased amounts of p21 (data not shown).

While it is likely that the composition of cyclin-CDK complexes is largely determined by the relative abundances and affinities of the cyclins, CDKs, and CDK inhibitors involved, it is also possible that interactions with other intracellular proteins contribute to the availability or association of these molecules. For example, a Myc-regulated heat-labile inhibitor of p21 has been described (20). By an apparently similar mechanism, in cells which express abundant p27 but little p21, Myc induction inhibits the ability of p27 to bind cyclin E-Cdk2, most likely by causing the p27 to be sequestered (34, 41, 62). While cyclin D-Cdk4 or cyclin D-Cdk6 complexes provide an attractive possibility for the sequestration of p27 or p21, increased association between these proteins and p27 was not observed following c-Myc induction (62). Similarly, data from this laboratory suggest that following c-Myc induction in human breast cancer cells, p21 and p27 are not sequestered by cyclin D-Cdk4 (43). Recent data suggest that the sequestered p27 is targeted for degradation, raising the possibility that the sequestering proteins are involved in the degradation process (34). It is possible that the decrease in c-myc expression following progestin treatment results in decreased expression of p21- and p27-sequestering molecules, contributing to increased availability of p21 and p27 for cyclin-CDK binding. However, the ability of cyclin D1 induction to restore CDK activity and cell cycle progression in progestin-pretreated cells suggests a more major role for cyclin expression than for c-myc expression in the redistribution of cyclin E-Cdk2 complexes.

Decreased CDK activity preceded inhibition of entry into S phase and thus provides a mechanism for inhibition of proliferation by progestins. However, no decreases in cyclin expression or CDK activity were apparent after less than 12 h of progestin treatment, indicating that while these are unlikely to be consequences of inhibition of proliferation, they are likely to be indirect effects of progestin action. Cell cycle kinetic studies of progestin inhibition in T-47D cells led